XML 98 R50.htm IDEA: XBRL DOCUMENT
v3.25.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Narrative) (Details) |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Apr. 06, 2018 USD ($) milestone | Apr. 05, 2018 USD ($) option | Sep. 30, 2019 USD ($) performanceObligation material_right | Dec. 31, 2024 USD ($) $ / shares | Dec. 31, 2023 USD ($) $ / shares
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Accounts receivable |  |  |  | $ 526,000 | $ 923,000
Deferred revenues |  |  |  | 7,556,000 | 0
Kite Pharma, Inc. |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Increase (decrease) in revenue |  |  |  |  | 13,900,000
Increase (decrease) in net loss |  |  |  |  | $ 13,900,000
Increase (decrease) in basic net loss per share | $ / shares |  |  |  |  | $ 0.08
Increase (decrease) in diluted net loss per share | $ / shares |  |  |  |  | $ 0.08
Kite Pharma, Inc. | License |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Contract with customer liability |  | $ 150,000,000 |  |  |
Number of remaining performance obligations | performanceObligation |  |  | 4 |  |
Number of material rights for renewal of research period | material_right |  |  | 2 |  |
Renewal period |  |  | 1 year |  |
Fixed consideration |  |  | $ 150,000,000 |  |
Kite Pharma, Inc. | Collaboration and License Agreement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone payments received | $ 150,000,000 |  |  |  |
Initial research term of agreement |  | 6 years |  |  |
Number of options to extend initial research term | option |  | 2 |  |  |
Extended research term of agreement |  | 1 year |  |  |
Separate fee for additional term |  | $ 10,000,000 |  |  |
Accounts receivable |  |  |  | 0 | $ 200,000
Deferred revenues |  |  |  | 0 | $ 0
Kite Pharma, Inc. | Collaboration and License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Contingent development and sales-based milestone payments to be received | 1,300,000,000 |  |  |  |
Kite Pharma, Inc. | Collaboration and License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Contingent development and sales-based milestone payments to be received | $ 1,800,000,000 |  |  |  |
Maximum amount of achieved milestones to receive payment | milestone | 10 |  |  |  |
Kite Pharma, Inc. | Collaboration and License Agreement | Maximum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Development and sales-based milestone payments to be received | $ 3,000,000,000 |  |  |  |
Kite Pharma, Inc. | Collaborative Arrangement | Change in Agreement Estimate, March and September 2023 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Increase (decrease) in revenue |  |  |  | 13,900,000 |
Increase (decrease) in net loss |  |  |  | $ 13,900,000 |
Increase (decrease) in basic net loss per share | $ / shares |  |  |  | $ 0.08 |
Increase (decrease) in diluted net loss per share | $ / shares |  |  |  | $ 0.08 |

X
- Definition Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent development and sales based milestone payments to be received. + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Extended Research Term Of Agreement + References No definition available. + Details
Name: | sgmo_ExtendedResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Earnings Per Share, Basic + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInEarningsPerShareBasic
Namespace Prefix: | sgmo_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Earnings Per Share, Diluted + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInEarningsPerShareDiluted
Namespace Prefix: | sgmo_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Net Income (Loss) Attributable To Parent + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Options To Extend Initial Research Term + References No definition available. + Details
Name: | sgmo_NumberOfOptionsToExtendInitialResearchTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Number Of Remaining Performance Obligations + References No definition available. + Details
Name: | sgmo_RevenueNumberOfRemainingPerformanceObligations
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Fixed Consideration Amount + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Renewal Period + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationRenewalPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Separate upfront fee. + References No definition available. + Details
Name: | sgmo_SeparateUpfrontFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarchAndSeptember2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |